Riskpilot← Back to searchSign inGet full accessSEQURNA AB
ABActiveOrg 5593986127Liljestrands Väg 10Manufacture of other chemical products n.e.c. · NACE 2059Est. 20221-4 employees
Revenue 2024
SEK 2,6M
+11750% vs 2023
EBITDA margin
77.3%
+2115% vs 2023
Equity ratio
91.8%
Financial strength
Net profit 2024
SEK 1,3M
+982% vs 2023
| Revenue | SEK 2,6M | +11750% |
| EBITDA | SEK 2M | +2115% |
| Net profit | SEK 1,3M | +982% |
| Total assets | SEK 12,8M | +1417% |
| Equity | SEK 11,8M | +2348% |
| Employees | — | — |
Legal name
SEQURNA AB
Org number
5593986127
Legal form
Aktiebolag
NACE code
2059 · Manufacture of other chemical products n.e.c.
Founded
26 september 2022
Share capital
SEK 34 000
Employees
1-4
VAT registered
Yes
Audit selected
No
Last report
2024-12-31
Financial year
January – December
Signatory rights
Firman tecknas av styrelsen Dessutom har verkställande direktören rätt att teckna firman beträffande löpande förvaltningsåtgärder
Company purpose
Företaget avser bedriva utvecklingsarbete, produktion och försäljning av medicintekniska produkter. Företaget avser också bedriva medicinteknisk konsultverksamhet och annan förenlig verksamhet inom medicinteknik.
Address
Liljestrands Väg 10
Email
bjorn.reinius@sequrna.com
Risika for professionals
Risika provides regulated workflow tools for finance, procurement and compliance teams that need monitoring, alerts and an API.
| Item | 2023 | 2024 |
|---|---|---|
| Revenue | 22 | 2 607 |
| Staff expenses | — | — |
| EBITDA | −100 | 2 015 |
| Depreciation & amort. | −44 | −107 |
| EBIT | −144 | 1 908 |
| Net financials | — | 126 |
| Profit before tax | −144 | 1 563 |
| Tax | −0 | −293 |
| Net profit | −144 | 1 270 |
| Item | 2023 | 2024 |
|---|---|---|
| Total assets | 844 | 12 803 |
| Equity | 480 | 11 750 |
| Long-term debt | 0 | 0 |
| Short-term debt | 364 | 582 |
| Total debt | 364 | 582 |
EBITDA margin
77.3%
This company
15.8%
Market median
+389% vs market
20232024
Equity ratio
91.8%
This company
38.2%
Market median
+140% vs market
20232024
Return on equity
10.8%
This company
18.4%
Market median
+41% vs market
20232024
Net profit margin
48.7%
This company
8.1%
Market median
+501% vs market
20232024
Asset turnover
0.20×
This company
1.12×
Market median
-82% vs market
20232024
Debt / equity
0.09×
This company
0.62×
Market median
+85% vs market
20232024
- Annual report 2024Filed via Bolagsverket / SCB · Period 2024-01-01 – 2024-12-31
- Annual report 2023Filed via Bolagsverket / SCB · Period 2022-09-01 – 2023-12-31
| Name | Role | Member since | Age | Other directorships |
|---|---|---|---|---|
AL Deputy Chief Executive Officer | Deputy Chief Executive Officer | 2022 | — | — |
BL Chief Executive Officer | Chief Executive Officer | 2022 | — | — |
JC Deputy Chief Executive Officer | Deputy Chief Executive Officer | 2022 | — | — |
HT Chief Auditor | Chief Auditor | 2024 | — | — |
| Name | Role | Member since | Age | Other directorships |
|---|---|---|---|---|
| Chairman | 2024 | — | — | |
| Board of Directors | 2024 | — | — |
No shareholder data available.
Beneficial ownership (UBO) data access is restricted in Denmark as of September 2025 per the EU 6th AML Directive. Learn more.
No registered parent or subsidiaries
Board members of SEQURNA AB also hold positions in 0 other companies.
| Person | Role here | Other companies |
|---|---|---|
| Antonio Lentini | Deputy Chief Executive Officer | 0 companies |
| Björn Lennart Reinius | Chief Executive Officer | 0 companies |
| Joyce Carol Noble | Deputy Chief Executive Officer | 0 companies |
| Hanna Terese Sewén | Chief Auditor | 0 companies |
| Hans Fredrik Olsson | Chairman | 0 companies |
| Rickard Sandberg | Board of Directors | 0 companies |